- Investing Ideas
- U.S. Pharmaceuticals & Biotech Sustainable Track Record
U.S. Pharmaceuticals & Biotech Sustainable Track Record
Results
12
Companies which have reinvested earnings to sustain 10% yearly growth over 5 years.
12 companies
CorMedix
Market Cap: US$652.7m
A biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States.
CRMD
US$8.27
7D
-6.8%
1Y
-27.3%
Protalix BioTherapeutics
Market Cap: US$192.6m
A biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system.
PLX
US$2.31
7D
-2.1%
1Y
67.4%
Rigel Pharmaceuticals
Market Cap: US$764.1m
A biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States.
RIGL
US$41.17
7D
-3.3%
1Y
117.8%
Aurinia Pharmaceuticals
Market Cap: US$2.1b
A biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan.
AUPH
US$15.98
7D
-1.5%
1Y
77.8%
Medpace Holdings
Market Cap: US$15.1b
Provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia.
MEDP
US$536.17
7D
-1.9%
1Y
71.5%
TG Therapeutics
Market Cap: US$7.8b
A commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.
TGTX
US$54.89
7D
-5.5%
1Y
44.6%
ACADIA Pharmaceuticals
Market Cap: US$4.4b
A biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America.
ACAD
US$25.49
7D
-2.7%
1Y
15.8%
Exelixis
Market Cap: US$14.1b
An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
EXEL
US$55.77
7D
-2.3%
1Y
26.6%
Catalyst Pharmaceuticals
Market Cap: US$3.9b
A commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States.
CPRX
US$31.49
7D
0%
1Y
50.3%
Eli Lilly
Market Cap: US$1.1t
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally.
LLY
US$1,152.54
7D
-6.7%
1Y
49.3%
Earth Science Tech
Market Cap: US$45.5m
Together with its subsidies, focuses on health and wellness industry.
ETST
US$0.16
7D
9.8%
1Y
-19.0%
CapForce
Market Cap: US$198.1m
A precision medicine company, develops and commercializes molecular microbiology solutions for life threatening infectious diseases in the United States and internationally.
CFOR
US$21.00
7D
27.3%
1Y
418.5%